FINSUM + Magnifi: Pharma Still a Value Play Despite Being a Key Industry in the Pandemic

(March 2021)

Most pharmaceutical companies kicked it into high gear to develop the Covid-19 vaccine, but they received very little investor attention compared to the overall market. Price to earnings ratios are among the lowest of any industry group in the S&P 500. Many drug companies will see their future earnings increase as we exit the pandemic because many American’s have halted their prescription use for smaller ailments during Covid. Pfizer has seen some of the most extreme value of the pharmaceutical companies, and ‘booster’ shots could sustain covid earnings. Lilly, AbbVie, Bristol Meyers, and Merck all have a promising future pipeline that could generate profits for future investors.
(Boston)

 


FINSUM + Magnifi: Drug stocks are trading extremely cheaply right now and their increased earnings aren’t all from the pandemic. Investors should take advantage of the one place they can find relatively low P/Es in the S&P right now.



New call-to-action

Magnifi is changing the way we shop for investments, with the world’s first semantic search engine for finance that helps users discover, compare and buy investment products such as ETFs, mutual funds and stocks. As of March 2021, 250,000+ users with $475+ Billion in Assets Under Influence, have used Magnifi over 1,200,000 times. Try it for yourself today.

 

This blog is sponsored by Magnifi. The information and data are as of the publish date unless otherwise noted and subject to change. This material is provided for informational purposes only and should not be construed as individualized investment advice or an offer or solicitation to buy or sell securities tailored to your needs. This information covers investment and market activity, industry or sector trends, or other broad-based economic or market conditions and should not be construed as investment research or advice. Investors are urged to consult with their financial advisors before buying or selling any securities. Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. Past performance is no guarantee of future results. This content may not be reproduced or distributed to any person in whole or in part without the prior written consent of Magnifi. [As a technology company, Magnifi provides access to tools and will be compensated for providing such access. Magnifi does not provide brokerage or custody services.]

 

New call-to-action

Magnifi in Action: Discover "Low Cost Drug Funds"

Click on any fund in the chart below to dig deeper.

 

 

 

Related Posts

FINSUM + Magnifi: Impact Investing is Changing Healthcare

September 27, 2021

FINSUM + Magnifi: Goldman Picks These Three Medical Stocks for a 100% Rally

June 25, 2021

FINSUM + Magnifi: Healthcare Will be a Headliner Even After the Pandemic

April 23, 2021

Healthcare has been one of the dominant stories of the pandemic, but its stock...

FINSUM + Magnifi: Why Healthcare ETFs are About to Win

(March 2021)

The multinational biopharmaceutical company Amgen has agreed to terms to acquire...